Home » Stocks » AGTC

Applied Genetic Technologies Corporation (AGTC)

Stock Price: $5.16 USD -0.10 (-1.90%)
Updated October 30, 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 133.43M
Revenue (ttm) 2.45M
Net Income (ttm) -45.89M
Shares Out 25.86M
EPS (ttm) -2.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day October 30
Last Price $5.16
Previous Close $5.26
Change ($) -0.10
Change (%) -1.90%
Day's Open 5.25
Day's Range 5.06 - 5.27
Day's Volume 71,364
52-Week Range 2.29 - 10.42

More Stats

Market Cap 133.43M
Enterprise Value 67.86M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.86M
Float 23.03M
EPS (basic) -2.17
EPS (diluted) -2.18
FCF / Share -2.02
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.55M
Short Ratio 7.21
Short % of Float 6.75%
Beta 2.47
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 54.39
PB Ratio 1.87
Revenue 2.45M
Operating Income -46.94M
Net Income -45.89M
Free Cash Flow -42.56M
Net Cash 65.57M
Net Cash / Share 2.54
Gross Margin -568.00%
Operating Margin -1,913.66%
Profit Margin -1,870.90%
FCF Margin -1,735.14%
ROA -30.48%
ROE -61.30%
ROIC -84.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$16.50*
(219.77% upside)
Low
12.0
Current: $5.16
High
26.0
Target: 16.50
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year202020192018201720162015201420132012
Revenue2.4541.6924.1939.4747.362.351.130.941.08
Revenue Growth-94.12%72.38%-38.73%-16.66%1911.94%108.5%19.85%-12.94%-
Gross Profit2.4541.6924.1939.4747.362.351.130.941.08
Operating Income-46.94-4.35-22.381.90-2.09-24.53-12.56-3.59-2.06
Net Income-45.89-2.01-21.300.41-1.38-24.32-15.91-4.99-1.92
Shares Outstanding21.1018.1618.1118.0717.8116.253.570.110.11
Earnings Per Share-2.17-0.11-1.180.02-0.08-1.50-4.46-45.78-17.65
Operating Cash Flow-41.62-23.46-32.52-31.0070.99-19.49-11.93-2.78-1.37
Capital Expenditures-0.94-0.16-0.66-0.74-2.47-0.23-0.16-0.35-0.01
Free Cash Flow-42.56-23.62-33.18-31.7468.52-19.71-12.09-3.13-1.38
Cash & Equivalents80.4682.0010512798.5361.6473.0722.890.82
Total Debt14.89-------1.02
Net Cash / Debt65.5782.0010512798.5361.6473.0722.89-0.20
Assets10092.2211914818190.1777.4125.492.82
Liabilities29.3013.5119.3532.5971.514.642.533.571.59
Book Value71.0278.7199.1811510985.5374.87-36.18-31.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Applied Genetic Technologies Corporation
Country United States
Employees 83
CEO Susan B. Washer

Stock Information

Ticker Symbol AGTC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AGTC
IPO Date March 27, 2014

Description

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.